This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Centre National De La Recherche Scientifique, Institut Pasteur, Sorbonne Université. Active years: 2020-2023.
Company Filing History:
2 out of 5,383 
2 out of 897 
2 out of 263 
Years Active: 2020-2023
Title: Innovations by Jean Defourny in Hearing Loss Treatment
Introduction
Jean Defourny is a notable inventor based in Paris, France. He has made significant contributions to the field of auditory health, particularly in the prevention and treatment of hearing loss and impairment. With a total of 2 patents, his work focuses on innovative approaches to address auditory challenges.
Latest Patents
Defourny's latest patents revolve around the use of gasdermin, specifically gasdermin A, B, C, D, DFNA5, and DFNB59 (or pejvakin). These inventions aim to modulate cellular redox homeostasis, with a preferred application of pejvakin as an antioxidant. Additionally, he has developed a virally-mediated gene therapy designed to restore genetically-impaired auditory and vestibular functions in individuals suffering from Usher syndrome. This gene therapy utilizes an AAV2/8 vector that expresses at least one USH1 gene product, preferably SANS.
Career Highlights
Throughout his career, Jean Defourny has worked with prestigious institutions such as Institut Pasteur and Sorbonne Université. His research and innovations have contributed to advancements in auditory health and gene therapy.
Collaborations
Defourny has collaborated with esteemed colleagues, including Paul Avan and Asadollah Aghaie. These partnerships have further enriched his research and development efforts in the field.
Conclusion
Jean Defourny's innovative work in the treatment of hearing loss showcases his dedication to improving auditory health through scientific advancements. His contributions are paving the way for future developments in gene therapy and auditory restoration.